AZN:Phase III Trial Of Sipavibart Met Main Goal In Preventing COVID-19 In Immunocompromised Patients

(RTTNews) - AstraZeneca's (AZN.L, AZN) sipavibart demonstrated a statistically significant reduction in the incidence of symptomatic COVID-19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population, as per the SUPERNOVA Phase III COVID-1 https://www.nasdaq.com/articles/azn:phase-iii-trial-of-sipavibart-met-main-goal-in-preventing-covid-19-in